Managing Vomiting on Wegovy (semaglutide 2.4 mg): The HealthRX.com Step-by-Step Protocol

How often does vomiting happen on 2.4 mg?

In three pooled placebo-controlled trials of adults with obesity or overweight, 2,116 people took Wegovy 2.4 mg once weekly for up to 68 weeks and 1,261 took placebo. Vomiting occurred in 24% versus 6%, nausea in 44% versus 16%, diarrhea in 30% versus 16%, and constipation in 24% versus 11%. Any gastrointestinal reaction occurred in 73% versus 47% [1]. Vomiting is among the label's most common adverse reactions, those with an incidence of 5% or more [1].

Most people who vomited did not stop treatment. Permanent discontinuation for any adverse reaction was 6.8% on Wegovy versus 3.2% on placebo, and the share who stopped specifically for vomiting was 1.2% versus 0% (nausea 1.8% versus 0.2%, diarrhea 0.7% versus 0.1%) [1]. In STEP 1, the 68-week trial of 1,961 adults, 4.5% of participants on semaglutide and 0.8% on placebo discontinued for GI events [2].

Vomiting was more frequent at the higher 7.2 mg dose. In two 72-week trials with 1,311 people on 7.2 mg, 304 on 2.4 mg and 303 on placebo, vomiting was reported by 22%, 16% and 6% respectively, and GI reasons led 3%, 3% and 0.3% to stop [1]. In the adolescent trial of 133 people on semaglutide 2.4 mg and 67 on placebo, vomiting was 36% versus 10% [1].

What does the label say about gastric emptying and gastroparesis?

Semaglutide is a GLP-1 receptor agonist that delays gastric emptying [1]. The label does not say semaglutide causes gastroparesis. Its warning on severe GI reactions says Wegovy is not recommended in patients with severe gastroparesis, and its postmarketing reports list ileus, intestinal obstruction and severe constipation including fecal impaction [1].

What should I watch for while vomiting on Wegovy?

Kidney injury from fluid loss. The label warns about acute kidney injury due to volume depletion and says to monitor renal function in people reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials, acute kidney injury occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with prior kidney impairment and during dose titration, and often after GI fluid loss [1].

Pancreatitis. The label says to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Wegovy and begin appropriate management [1]. Confirmed acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 per 100 patient-years) versus 1 on placebo, and average amylase rose about 15% to 16% and lipase about 39%, with unknown significance in the absence of symptoms [1].

Allergic reactions. Anaphylaxis and angioedema have been reported. The label says to discontinue Wegovy if a serious hypersensitivity reaction is suspected and to promptly seek medical advice [1].

Severe GI reactions. The label warns that use has been associated with gastrointestinal adverse reactions, sometimes severe; severe GI reactions occurred in 4.1% on Wegovy versus 0.9% on placebo [1].

Gallbladder disease. Cholelithiasis was reported by 1.6% on Wegovy injection versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% in adult weight-management trials [1].

What happens if I miss an injection while vomiting?

The label's rule for the weekly injection is to take a missed dose if the next scheduled dose is more than 2 days away. After 2 or more consecutive missed doses, it calls for re-escalating from a lower dose [1]. Semaglutide's elimination half-life is about one week, so the drug stays in the body for roughly 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [1].

Does the label name an anti-nausea medicine?

No. The Wegovy label does not name ondansetron, promethazine, prochlorperazine or any other antiemetic for vomiting [1].

Separately, the label notes that delayed gastric emptying may affect the absorption of oral medicines, and it advises increased clinical or laboratory monitoring for oral drugs with a narrow therapeutic index or that require clinical monitoring [1].